Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients

Figures & data

Table 1 Biodemographical and clinical characteristics of Brazilian kidney transplant recipients and donors

Variables	Patients, n=148
Recipients
Age (years)	45.4±12.9
Body weight (kg)	66.3±12.6
Sex, male	103 (69.6)
Ethnicity
White	69 (46.6)
Mixed	53 (35.8)
African	18 (12.2)
Others	8 (5.4)
Comorbidities
Hypertension	77 (52.0)
Diabetes	19 (12.8)
Dyslipidemia	4 (2.7)
Biopsy-confirmed acute rejectiona	36 (24.3)
Delayed graft functionb	29 (19.6)
Donors
Age (years)	43.4±10.3
Sex, male	68 (45.9)
Missing data	1 (0.7)
Living donor	87 (58.8)
Ethnicity
White	82 (55.4)
Mixed	46 (31.1)
African	14 (9.5)
Others	4 (2.7)
Missing data	2 (1.3)
Immunosuppression at 90 days
Tacrolimus concentration (ng/mL)	5.9±2.6
Mycophenolate sodium dose (mg/day)	1377.9±200.5
Prednisone dose (mg/day)	5.6±3.0

Notes: Values are represented as n (%). Age, body weight, and concentration and doses of the immunosuppressive drugs are presented as mean ± standard deviation.

a Cumulative incidence.

b Defined as the use of dialysis within 7 days of the transplant.

Table 2 Logistic regression analysis of association of PPP3CA c.249G>A polymorphism with clinical outcomes up to 90 days after kidney transplantation

Dependent variable	Unadjusted logistic regression		Adjusted logistic regressiona
	OR (95% CI)	p	OR (95% CI)	p
Adverse events
Gastrointestinal disorders	0.86 (0.30–2.45)	0.773	0.75 (0.24–2.40)	0.630
Constipation	0.54 (0.15–1.99)	0.357	0.34 (0.07–1.61)	0.172
Diarrhea	0.90 (0.30–2.69)	0.847	1.08 (0.34–3.38)	0.899
Dyspeptic syndrome	0.93 (0.25–3.48)	0.915	0.80 (0.20–3.18)	0.754
Nausea and/or vomiting	0.89 (0.19–4.24)	0.884	0.42 (0.05–3.54)	0.428
Infections and infestations	1.29 (0.46–3.66)	0.631	1.45 (0.47–4.52)	0.518
Metabolism and nutrition disorders	1.00 (0.33–3.02)	0.994	1.31 (0.41–4.17)	0.645
Nervous system disorders	0.93 (0.31–2.79)	0.899	0.96 (0.31–3.02)	0.945
Headache	1.42 (0.37–5.47)	0.606	1.25 (0.31–5.10)	0.756
Renal and urinary disorders	1.60 (0.58–4.44)	0.367	1.85 (0.63–5.45)	0.267
Blood and lymphatic system disorders	3.05 (1.10–8.48)	0.032	2.66 (0.87–8.13)	0.086
Anemia	2.92 (0.98–8.72)	0.055	2.42 (0.70–8.29)	0.161
Musculoskeletal and connective tissue disorders	1.33 (0.40–4.41)	0.642	1.27 (0.36–4.48)	0.709
Skin and subcutaneous tissue disorders	0.32 (0.04–2.57)	0.286	0.40 (0.05–3.25)	0.389
Biopsy-confirmed acute rejection	1.67 (0.58–4.82)	0.346	2.27 (0.73–6.99)	0.154
Delayed graft function	1.70 (0.55–5.22)	0.355	1.27 (0.37–4.40)	0.706

Notes: Reference: PPP3CA c.249GG.

a Adjusted for body weight and CYP3A5*3C (rs776746) SNP status. Bold indicates significance.

Abbreviations: OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism.